Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial

Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial

Background. Elderly persons often experience a reduced immune response to influenza vaccination. We evaluated the usual dose of AS03A-adjuvanted H5N1 pandemic vaccine (3.75 μg hemagglutinin of A/Vietnam/1194/2004-like strain) compared with a double dose in an elderly population.

Bibliographic Details
Main Authors: Heijmans, Stéphane, De Meulemeester, Marc, Reynders, Paul, Giet, Didier, Demanet, Etienne, Devresse, Pierre-Yves, Icardi, Giancarlo, Dramé, Mamadou, Roman, François, Gillard, Paul
Format: Online
Language:English
Published: Oxford University Press 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068020/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068020/

Similar Items